NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $145.59 +1.34 (+0.93%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$144.57▼$146.7350-Day Range$136.64▼$148.6752-Week Range$119.59▼$150.59Volume1.07 million shsAverage Volume993,031 shsMarket Capitalization$16.17 billionP/E Ratio19.59Dividend Yield2.06%Price Target$149.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Quest Diagnostics alerts: Email Address Quest Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.31 Rating ScoreUpside/Downside2.6% Upside$149.38 Price TargetShort InterestHealthy2.06% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-0.62Upright™ Environmental ScoreNews Sentiment0.69Based on 43 Articles This WeekInsider TradingSelling Shares$306,494 Sold Last QuarterProj. Earnings Growth7.42%From $8.89 to $9.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.52 out of 5 starsMedical Sector106th out of 936 stocksMedical Laboratories Industry5th out of 18 stocks 1.2 Analyst's Opinion Consensus RatingQuest Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageQuest Diagnostics has only been the subject of 4 research reports in the past 90 days.Read more about Quest Diagnostics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.06% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 0.44%, indicating that investor sentiment is decreasing. Previous Next 4.2 Dividend Strength Dividend YieldQuest Diagnostics pays a meaningful dividend of 2.08%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 40.38%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 31.41% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuest Diagnostics has received a 74.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private clinical drug testing", "Private genetic testing services", and "Private oncology diagnostics services" products. See details.Environmental SustainabilityThe Environmental Impact score for Quest Diagnostics is -0.62. Previous Next 2.6 News and Social Media Coverage News SentimentQuest Diagnostics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Quest Diagnostics this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for DGX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows8 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $306,494.00 in company stock.Percentage Held by InsidersOnly 0.79% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 7.42% in the coming year, from $8.89 to $9.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 19.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.35.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 19.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.32.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 3.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quest Diagnostics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Quest Diagnostics Stock (NYSE:DGX)Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Read More DGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DGX Stock News HeadlinesJuly 26 at 7:13 PM | markets.businessinsider.comMaintaining Neutral Hold on Quest Diagnostics Amid Modest Growth and Pending Strategic InsightsJuly 26 at 4:04 AM | americanbankingnews.comRobert W. Baird Raises Quest Diagnostics (NYSE:DGX) Price Target to $154.00July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 25 at 7:56 AM | americanbankingnews.comQuest Diagnostics Incorporated Expected to Earn Q3 2024 Earnings of $2.28 Per Share (NYSE:DGX)July 25 at 6:45 AM | prnewswire.comBD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other DiseasesJuly 24 at 12:31 PM | americanbankingnews.comQuest Diagnostics (NYSE:DGX) Releases FY 2024 Earnings GuidanceJuly 24 at 11:15 AM | americanbankingnews.comQuest Diagnostics (NYSE:DGX) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPSJuly 24 at 10:27 AM | finance.yahoo.comQuest Diagnostics Incorporated's (NYSE:DGX) Intrinsic Value Is Potentially 95% Above Its Share PriceJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 24 at 10:27 AM | msn.comQuest Diagnostics Incorporated (NYSE:DGX) Q2 2024 Earnings Call TranscriptJuly 24 at 12:25 AM | markets.businessinsider.comBuy Rating Affirmed for Quest Diagnostics Amid Strong Q2 Financials and Upbeat 2024 GuidanceJuly 23 at 7:23 PM | seekingalpha.comQuest Diagnostics Incorporated (DGX) Q2 2024 Earnings Call TranscriptJuly 23 at 7:23 PM | markets.businessinsider.comQuest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst SaysJuly 23 at 11:02 AM | investorplace.comDGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024July 23 at 8:19 AM | reuters.comQuest Diagnostics raises 2024 profit, revenue forecasts on health tests demandJuly 23 at 6:45 AM | prnewswire.comQuest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024July 23 at 1:34 AM | americanbankingnews.comQuest Diagnostics (NYSE:DGX) Upgraded by StockNews.com to "Buy"July 22, 2024 | markets.businessinsider.comQuest Diagnostics Market Position and Earnings Potential: Analyst Pito Chickering’s Outlook amidst Inflationary Challenges and Growth StrategiesSee More Headlines Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 7/22 Dividend7/08/2024Dividend Payable7/22/2024Last Earnings7/23/2024Today7/26/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CUSIP74834L10 CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees48,000Year Founded1967Price Target and Rating Average Stock Price Target$149.38 High Stock Price Target$165.00 Low Stock Price Target$130.00 Potential Upside/Downside+2.6%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$7.43 Trailing P/E Ratio19.59 Forward P/E Ratio16.38 P/E Growth3.05Net Income$854 million Net Margins8.99% Pretax Margin11.94% Return on Equity15.35% Return on Assets7.19% Debt Debt-to-Equity Ratio0.57 Current Ratio1.00 Quick Ratio0.89 Sales & Book Value Annual Sales$9.25 billion Price / Sales1.75 Cash Flow$12.90 per share Price / Cash Flow11.29 Book Value$59.92 per share Price / Book2.43Miscellaneous Outstanding Shares111,090,000Free Float110,214,000Market Cap$16.17 billion OptionableOptionable Beta0.89 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James E. Davis (Age 61)Chairman, CEO & President Comp: $2.88MMr. Sam A. Samad (Age 54)Executive VP & CFO Comp: $1.33MMr. Michael E. Prevoznik (Age 62)Senior VP & General Counsel Comp: $881.23kMs. Catherine T. Doherty (Age 61)Executive Vice President of Regional Businesses Comp: $1MMr. Karthik Kuppusamy Ph.D. (Age 54)Senior Vice President of Clinical Solutions Comp: $840.3kMr. Michael J. Deppe (Age 57)Senior VP, Corporate Controller & Chief Accounting Officer Mr. Murali BalakumarSenior VP, Chief Information & Digital OfficerMr. Shawn C. BevecVice President of Investor RelationsMs. Kristin Lee Wallace Esq.Senior VP & Chief Compliance OfficerMr. Gary D. SamuelsSenior VP & Chief Communications OfficerMore ExecutivesKey CompetitorsLaboratory Co. of AmericaNYSE:LHDaVitaNYSE:DVAChemedNYSE:CHER1 RCMNASDAQ:RCMCorVelNASDAQ:CRVLView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 14,347 shares on 7/26/2024Ownership: 0.712%State of Michigan Retirement SystemBought 100 shares on 7/26/2024Ownership: 0.030%Allspring Global Investments Holdings LLCBought 222 shares on 7/26/2024Ownership: 0.005%Checchi Capital Advisers LLCSold 78 shares on 7/26/2024Ownership: 0.002%Mitsubishi UFJ Asset Management UK Ltd.Sold 2,000 shares on 7/26/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $137.88 at the beginning of 2024. Since then, DGX stock has increased by 5.6% and is now trading at $145.59. View the best growth stocks for 2024 here. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) announced its earnings results on Tuesday, July, 23rd. The medical research company reported $2.35 EPS for the quarter, beating analysts' consensus estimates of $2.31 by $0.04. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' board authorized a stock buyback plan on Thursday, February 2nd 2023, which allows the company to buy back $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's board of directors believes its shares are undervalued. What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO? 1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Glassdoor.com. Steve Rusckowski has an approval rating of 78% among the company's employees. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. Who are Quest Diagnostics' major shareholders? Top institutional investors of Quest Diagnostics include Bank of New York Mellon Corp (0.71%), Van Lanschot Kempen Investment Management N.V. (0.32%), M&G Plc (0.30%) and Sumitomo Mitsui Trust Holdings Inc. (0.26%). Insiders that own company stock include Stephen H Rusckowski, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Timothy M Ring, Vicky B Gregg, Karthik Kuppusamy, Mark E Delaney and Gail R Wilensky. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE) and Abbott Laboratories (ABT). This page (NYSE:DGX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
